Drug updated on 9/4/2024
Dosage Form | Injection (intravenous; 1,000 mcg/1 mL) |
Drug Class | CD123-directed cytotoxins |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.
Latest News
Summary
- Elzonris (tagraxofusp-erzs) is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients 2 years and older.
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- Tagraxofusp (Elzonris) demonstrates effectiveness in treating both newly diagnosed and relapsed/refractory BPDCN patients, including facilitating successful bridging to hematopoietic stem cell transplantation (HSCT).
- High rates of effectiveness are observed in adult populations, including treatment-naïve and previously treated patients, with a more limited but still effective experience in pediatric patients.
- There is a notable difference in the extent of data available between adult and pediatric populations, with more extensive data supporting the effectiveness in adults.
- Tagraxofusp is generally safe for use in both treatment-naïve and previously treated adult patients, and it also demonstrates safety in pediatric patients aged 2 years and older, though with more limited experience.
- The most significant safety concern identified is the risk of potentially fatal capillary leak syndrome, necessitating careful patient selection and monitoring.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Elzonris (tagraxofusp-erzs) Prescribing Information. | 2022 | Stemline Therapeutics, Inc., New York, NY |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Recent advances in the biology and CD123-directed treatment of blastic plasmacytoid dendritic cell neoplasm. | 2024 | Clinical Lymphoma, Myeloma & Leukemia |
Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm. | 2020 | Hematology/Oncology Clinics of North America |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations. | 2024 | Leukemia & Lymphoma |
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on standards of care and areas of need. | 2023 | Blood |
Clinical insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm. | 2022 | Cancer Management and Research |
Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm. | 2020 | Blood Advances |